Worst performance and only double-digit loser this week was OPTI:Optibiotix, which dropped 10%. I suspect this was mostly down to existing holders selling their shares in order to buy the spin-off SBTX:SkinBioTherapeutics. It battered my potential profits though.
Not double digits, but JLP:Jubilee Platinum fell 8% and also crippled my potential profits, so it's all the more remarkable that everything is up by £991 at the end of the week.
That increase is thanks to a host of great performers. IQE:IQE wasn't double digit, but 8% was very nice. The first double-digit riser was SBTX:SkinBioTherapeutics which rose 13% and vindicated my decision to buy early. It has already wiped out the £90 loss I took to sell VEC:Vectura to raise the cash.
Next great performance was CAML:Central Asia Metals which has been slipping for no real reason lately, but climbed 22% this week to recover nearly all the recent losses.
Star Share was KIBO:Kibo Mining, which was absolutely soaring all week and went from £1,500 loss last week to £245 profit on Thursday. Tragically there was a re-trace today and it dropped 7.5% and back to a £280 loss. Hopefully that was just profit taking and the sentiment that has driven the share in the early part of the week will return next week.
Here's the ISA and share accounts performance
| Weekly Change | |||
| Portfolio cost | £42,964.02 | -£92.97 | |
| Portfolio sell value (bid price - commission) | £42,193.30 | (-1.8%) | +£314.91 |
| Potential profits | £4,082.42 | -£583.43 | |
| Yr 2 Dividends | £357.10 | +£0 | |
| Yr 2 Profit from sales | £3,314.79 | -£89.44 | |
| Yr 2 Average monthly cash profit | £451.37 | -£24.67 | |
| Yr 2 Avg annual % of current portfolio cost | 12.6% | ||
| Total Dividends | £1,025.03 | +£0 | |
| Total Profit from sales | £7,155.05 | -£89.44 | |
| Average monthly cash profit | £403.12 | -£9.20 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 11.3% |
The sale of VEC:Vectura for a £89.44 loss meant the portfolio cost dropped when I bought SBTX:SkinBioTherapeutics, as it was 5th April and I couldn't top up the ISA any more. This affected the average monthly performance too, with bigger drops than usual. I had hoped to bed AMYT:Amryt Pharma and JLP:Jubilee Platinum into my ISA today, but for some reason Hargreaves Lansdown didn't process the order so I cancelled it this evening. I don't want to risk something happening over the weekend that causes massive volatility in the market next week, and let's face it, there's a reasonably good chance of it!
The potential profits were hammered, losing £583 with the drops in OPTI:Optibiotix and JLP:Jubilee Platinum. Most of the improvement that allowed the portfolio value to go up was KIBO:Kibo Mining reducing losses.
It was probably a bit too much to hope for that the green line would meet the red this week. It came so close yesterday, but the gap is only £770 so a recovery in the shares that fell this week could fill that gap quickly.
I've removed the trend lines from the graphs - I decided they didn't really add much and were making it harder to see what was going on.
The SIPP looks like this after week 71
| Weekly Change | |||
| Portfolio cost | £16,776.69 | +£0 | |
| Portfolio sell value (bid price - commission) | £20,138.00 | (+20%) | +£506.61 |
| Potential profits | £3,950.30 | +£496.41 | |
| Yr 2 Dividends | £0 | +£0 | |
| Yr 2 Profit from sales | £842.07 | +£0 | |
| Yr 2 Average monthly cash profit | £185.67 | -£10.31 | |
| Yr 2 Avg annual % of current portfolio cost | 13.3% | ||
| Total Dividends | £413.19 | +£0 | |
| Total Profit from sales | £3,191.93 | +£0 | |
| Average monthly cash profit | £215.23 | -£3.07 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 15.4% |
A really good week for the SIPP, mainly thanks to CAML:Central Asia Metals rising 22% and IQE:IQE performing well. That allowed the OPT:Optibiotix and JLP:Jubilee Platinum drops to be swallowed up. Just imagine what a week it would have been if they hadn't dropped!
Back to a widening habit - good to see.
The trading portfolio now looks like this
| Weekly Change | |||
| Portfolio cost | £1,481.98 | +£0 | |
| Cash | £79.63 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,385.03 | (-6.5%) | +£169.65 |
| Potential profits | £0 | +£0 | |
| Dividends | £0 | +£0 | |
| Profit from sales | £61.57 | +£0 | |
| Average monthly cash profit | £7.21 | -£0.20 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 5.8% |
A good week for a change, mainly thanks to KIBO:Kibo Mining going into profit. I wish I'd sold them on Thursday before the 7.5% drop - must remember this account is meant to be for quick gains, not long term investing. I think I'll avoid selling shares in this account as a live transaction, but when they get to the price I want, I'll put a fairly tight stop-loss on them so I can follow them up if they continue to climb.
There is one thing I have to do with this account, which is get back the third £500 I added. My car cost £800 to get through its MOT today, on the same day I paid a £1,250 deposit on a holiday. The £500 has to plug some of that hole, so when I sell Kibo next week, I'll keep the profit in the account but take out the £500.
So as usual, as some shares recover others fall. Given all the goings on this week, I'm very pleased with the performance. SBTX:SkinBioTherapeutics has exceeded expectations following IPO and OPTI:Optibiotix CEO Steve O'Hara said that he would consider returning value to shareholders following the spin-off once the shares were up by 20-30%. Well they floated at 9p and are now at 16.25p which I make 80%. That's a lot of profit to Optibiotix who own half the shares. That's why it's a mystery the Optibiotix share price tanked 10% this week.
Let's see how the story unfolds...
No comments:
Post a Comment